# Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study

> **NCT01077908** · PHASE3 · COMPLETED · sponsor: **Cell Medica Ltd** · enrollment: 89 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **BIOLOGICAL:** Adoptive Cellular Therapy
- **DRUG:** Best available antiviral drug therapy

## Key facts

- **NCT ID:** NCT01077908
- **Lead sponsor:** Cell Medica Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2018-01-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077908, "Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01077908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*